Skip to main navigation Skip to search Skip to main content

A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy

  • Pavel G. Komarov
  • , Elena A. Komarova
  • , Roman Kondratov
  • , Konstantin Christov-Tselkov
  • , John S. Coon
  • , Mikhail V. Chernov
  • , Andrei V. Gudkov
  • The University of Illinois at Chicago
  • Rush University Medical Center
  • Quark Biotech, Inc.
  • Cleveland Clinic Foundation

Research output: Contribution to journalArticlepeer-review

1185 Scopus citations

Abstract

Chemotherapy and radiation therapy for cancer often have severe side effects that limit their efficacy. Because these effects are in part determined by p53-mediated apoptosis, temporary suppression of p53 has been suggested as a therapeutic strategy to prevent damage of normal tissues during treatment of p53-deficient tumors. To test this possibility, a small molecule was isolated for its ability to reversibly block p53-dependent transcriptional activation and apoptosis. This compound, pifithrin-α, protected mice from the lethal genotoxic stress associated with anticancer treatment without promoting the formation of tumors. Thus, inhibitors of p53 may be useful drugs for reducing the side effects of cancer therapy and other types of stress associated with p53 induction.
Original languageEnglish
Pages (from-to)1733-1737
Number of pages5
JournalScience
Volume285
Issue number5434
DOIs
StatePublished - Sep 10 1999

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this